{"id":1221,"date":"2020-05-22T01:32:02","date_gmt":"2020-05-22T01:32:02","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=1221"},"modified":"2023-08-29T18:02:05","modified_gmt":"2023-08-29T18:02:05","slug":"invex-therapeutics-raises-plans-phase-3-clinical-trial","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=1221","title":{"rendered":"Invex Therapeutics\u516c\u53f8\u7b79\u96c6\u4e862600\u4e07\u6fb3\u5143\uff0c\u8ba1\u5212\u8fdb\u884c\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c"},"content":{"rendered":"<p>\u4e24\u5929\u4ee5\u6765\u53d1\u5e03\u5176\u7b2c\u4e8c\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u548c\u201c\u660e\u786e\u8bc1\u636e\u201d\u5ba3\u5e03\u5176Exeatide\u836f\u7269\u662f\u6709\u6548\u964d\u4f4e\u9885\u5185\u538b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b(IIH)\u75c5\u4eba,<a href=\"http:\/\/smallcaps-production.test\/stocks\/?symbol=IXC&amp;lang=cn\">Invex Therapeutics (ASX: IXC)<\/a>\u8ddf\u8fdb\u4eca\u5929\u65e9\u4e0a\u5ba3\u5e03\u6210\u529f\u76842620\u4e07\u6fb3\u5143\u878d\u8d44\u7684\u5f62\u5f0f\u914d\u80a1\u3002<\/p>\n<p>\u5468\u4e09\uff0cInvex\u5ba3\u5e03\u5176\u4e34\u5e8a\u8bd5\u9a8c\u5728\u4e3b\u8981\u7ec8\u70b9\u548c\u4e00\u4e9b\u5173\u952e\u7684\u6b21\u8981\u7ec8\u70b9\u663e\u793a\u4e86\u201c\u660e\u786e\u7684\u7597\u6548\u7edf\u8ba1\u548c\u4e34\u5e8a\u8bc1\u636e\u201d\uff0c\u8fd9\u8868\u660e\u60a3\u8005\u572812\u5468\u540e\u7acb\u5373\u964d\u4f4e\u4e86\u9885\u5185\u538b\uff0c\u5e76\u83b7\u5f97\u4e86\u5f3a\u6709\u529b\u7684\u3001\u6301\u7eed\u7684\u4e34\u5e8a\u76ca\u5904\u3002<\/p>\n<p>\u6b64\u5916\uff0c\u8bd5\u9a8c\u8fd8\u663e\u793a\uff0c\u57282.5\u5c0f\u65f6\u300124\u5c0f\u65f6\u548c12\u5468\u7684\u65f6\u95f4\u70b9\uff0cExeatide\u201c\u5728\u7edf\u8ba1\u5b66\u4e0a\u663e\u8457\u201d\u964d\u4f4e\u4e86\u9885\u5185\u538b\uff0cInvex\u5c06\u5176\u63cf\u8ff0\u4e3a\u201c\u5feb\u901f\u548c\u6301\u7eed\u201d\u3002<\/p>\n<p>\u5728\u6b21\u8981\u7ec8\u70b9\u5305\u62ec\u5934\u75db\u548c\u89c6\u529b\u65b9\u9762\uff0cExeatide\u4e5f\u663e\u793a\u51fa\u548c\u853c\u7684\u7ed3\u679c\u3002<\/p>\n<p>\u6d4b\u91cf\u7684\u5934\u75db\u9891\u7387\u7a81\u51fa\u4e86\u7edf\u8ba1\u4e0a\u663e\u8457\u7684\uff0c\u6709\u76ca\u7684\u51cf\u5c11\u6bcf\u6708\u5934\u75db\u5929\u6570\u7684Exenatide\u6cbb\u7597\u7684\u60a3\u8005\u3002<\/p>\n<p>\u5728\u89c6\u529b\u65b9\u9762\uff0c\u8bd5\u9a8c\u8bc1\u660e\uff0c\u670d\u7528Exenatide\u7684\u60a3\u8005\u201c\u5728\u7edf\u8ba1\u5b66\u4e0a\u6709\u663e\u8457\u6539\u5584\u201d\u3002<\/p>\n<p>\u8be5\u516c\u53f8\u8868\u793a:\u201c\u6211\u4eec\u76f8\u4fe1\uff0c\u8fd9\u4e9b\u4e8c\u671f\u6570\u636e\u6709\u529b\u5730\u652f\u6301\u5c06Presendin (Invex\u7684\u4e13\u5229Exenatide\u914d\u65b9)\u57282021\u5e74\u4e0a\u534a\u5e74\u8f6c\u5165\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\u201d<\/p>\n<p>\u6839\u636eInvex\u8463\u4e8b\u957fJason Loveridge\u535a\u58eb\u7684\u8bf4\u6cd5\uff0c\u5728\u8bbe\u8ba1\u548c\u6267\u884cInvex\u7684\u5355\u671f3\u671f\u6ce8\u518c\u7814\u7a76\u65f6\uff0c\u8bd5\u9a8c\u7684\u6570\u636e\u662f\u201c\u65e0\u4ef7\u7684\u201d\uff0c\u5e76\u201c\u589e\u52a0\u4e86\u6211\u4eec\u7684\u4fe1\u5fc3\uff0c\u5373Presendin\u5c06\u88ab\u8bc1\u660e\u662f\u4e00\u4e2a\u6709\u4ef7\u503c\u7684\u6cbb\u7597\u65b9\u6848\uff0c\u5bf9\u60a3\u6709IIH\u7684\u60a3\u8005\uff0c\u76ee\u524d\u6ca1\u6709\u6279\u51c6\u6216\u6709\u6548\u7684\u836f\u7269\u3002\u201d<\/p>\n<h2>\u878d\u8d44\u53d1\u5c55<\/h2>\n<p>\u51ed\u501f\u5f3a\u52b2\u7684\u4e1a\u7ee9\u548c\u5373\u5c06\u8fdb\u884c\u7684\u4e09\u671f\u8bd5\u9a8c\uff0cInvex\u8fc5\u901f\u5411\u673a\u6784\u6295\u8d44\u8005\u3001\u4e13\u4e1a\u4eba\u58eb\u3001\u7ecf\u9a8c\u4e30\u5bcc\u7684\u6fb3\u5927\u5229\u4e9a\u548c\u6d77\u5916\u6295\u8d44\u8005\u8fdb\u884c\u4e86\u914d\u552e\uff0c\u7b79\u96c6\u4e862,620\u4e07\u6fb3\u5143\u3002<\/p>\n<p>Invex\u4ee5\u6bcf\u80a11.30\u6fb3\u5143\u7684\u53d1\u884c\u4ef7\u53d1\u884c\u4e862,015\u4e07\u80a1\u5df2\u7f34\u8db3\u80a1\u672c\u7684\u65b0\u666e\u901a\u80a1\uff0c\u8f83\u5e02\u573a\u5e73\u5747\u4ef7\u683c\u7ea6\u67094%\u7684\u6298\u8ba9\uff0c\u8f83\u516c\u53f85\u670818\u65e5\u505c\u724c\u524d\u7684\u6536\u76d8\u4ef7\u670913%\u7684\u6298\u8ba9\u3002<\/p>\n<p>\u6b64\u6b21\u914d\u80a1\u8ba1\u5212\u5206\u4e24\u6279\u8fdb\u884c:\u7b2c\u4e00\u6279\u5c06\u4ee5\u6bcf\u80a11.30\u6fb3\u5143\u7684\u4ef7\u683c\u53d1\u884c1,250\u4e07\u80a1\uff0c\u7b79\u8d441,625\u4e07\u6fb3\u5143;\u7b2c\u4e8c\u6279\u5c06\u4ee5\u6bcf\u80a11.30\u6fb3\u5143\u7684\u4ef7\u683c\u518d\u53d1\u884c765\u4e07\u80a1\uff0c\u7b79\u8d44995\u4e07\u6fb3\u5143\u3002<\/p>\n<p>\u7136\u800c\uff0cTranche 2\u7684\u5b8c\u6210\u53d6\u51b3\u4e8eInvex\u7684\u7279\u522b\u80a1\u4e1c\u5927\u4f1a(EGM)\u7684\u6279\u51c6\uff0c\u9884\u8ba12020\u5e746\u670829\u65e5\u6216\u524d\u540e\u4e3e\u884c\u3002<\/p>\n<p>\u8be5\u516c\u53f8\u4ece\u73b0\u6709\u6295\u8d44\u8005\u90a3\u91cc\u83b7\u5f97\u4e86\u603b\u8ba11050\u4e07\u6fb3\u5143\u7684\u57fa\u77f3\u6295\u8d44\u627f\u8bfa\uff0c\u5176\u4e2d500\u4e07\u7f8e\u5143\u6765\u81eaTattarang\uff0c\u5373\u524dMinderoo Group\u3002<\/p>\n<p>Loveridge\u535a\u58eb\u89e3\u91ca\u8bf4\uff0cInvex\u516c\u53f8\u5c06\u5229\u7528\u7b79\u96c6\u5230\u7684\u8d44\u91d1\u8fdb\u884c\u7b2c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5e76\u8d44\u52a9\u7b2c\u4e8c\u4e2a\u4e34\u5e8a\u9879\u76ee\uff0c\u5f88\u53ef\u80fd\u662fIIH-WOP\uff0c\u8fd9\u662f\u7b2c\u4e8c\u4e2a\u5b64\u513f\u9002\u5e94\u75c7\u3002<\/p>\n<p>\u4ed6\u8bf4:\u201c\u8fd9\u7b14\u8d44\u91d1\u4e3a\u8be5\u516c\u53f8\u63d0\u4f9b\u4e86\u4e00\u4e2a\u6e05\u6670\u7684\u8f68\u8ff9\uff0c\u4f7f\u5176\u80fd\u591f\u5728\u5e02\u573a\u4e0a\u6ca1\u6709\u4efb\u4f55\u6279\u51c6\u6cbb\u7597\u7684\u91cd\u8981\u5b64\u513f\u75be\u75c5\u4e2d\u83b7\u5f97III\u671f\u4e34\u5e8a\u7ed3\u679c\u3002\u201d<\/p>\n<p>\u5728\u914d\u552e\u5b8c\u6210\u540e\uff0cInvex\u8868\u793a\uff0c\u73b0\u91d1\u6ce8\u5165\u5c06\u4f7f\u8be5\u516c\u53f8\u8d22\u52a1\u72b6\u51b5\u826f\u597d\uff0c\u7ea63,660\u4e07\u6fb3\u5143\u73b0\u91d1\u5c06\u6ee1\u8db3\u5176\u4e34\u5e8a\u548c\u5176\u4ed6\u76ee\u6807\u3002<\/p>\n<p>Invex\u80a1\u4ef7\u5728\u65e9\u76d8\u4ea4\u6613\u4e2d\u4e0a\u6da8\u8d85\u8fc716%\uff0c\u8fbe\u52301.74\u6fb3\u5143\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4e24\u5929\u4ee5\u6765\u53d1\u5e03\u5176\u7b2c\u4e8c\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u548c\u201c\u660e\u786e\u8bc1\u636e\u201d\u5ba3\u5e03\u5176Exeatide\u836f\u7269\u662f\u6709\u6548\u964d\u4f4e\u9885\u5185\u538b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b(IIH)\u75c5\u4eba,Invex Therapeutics (ASX: IXC)\u8ddf\u8fdb\u4eca\u5929\u65e9\u4e0a\u5ba3\u5e03\u6210\u529f\u76842620\u4e07\u6fb3\u5143\u878d\u8d44\u7684\u5f62\u5f0f\u914d\u80a1\u3002 \u5468\u4e09\uff0cInvex\u5ba3\u5e03\u5176\u4e34\u5e8a\u8bd5\u9a8c\u5728\u4e3b\u8981\u7ec8\u70b9\u548c\u4e00\u4e9b\u5173\u952e\u7684\u6b21\u8981\u7ec8\u70b9\u663e\u793a\u4e86\u201c\u660e\u786e\u7684\u7597\u6548\u7edf\u8ba1\u548c\u4e34\u5e8a\u8bc1\u636e\u201d\uff0c\u8fd9\u8868\u660e\u60a3\u8005\u572812\u5468\u540e\u7acb\u5373\u964d\u4f4e\u4e86\u9885\u5185\u538b\uff0c\u5e76\u83b7\u5f97\u4e86\u5f3a\u6709\u529b\u7684\u3001\u6301\u7eed\u7684\u4e34\u5e8a\u76ca\u5904\u3002 \u6b64\u5916\uff0c\u8bd5\u9a8c\u8fd8\u663e\u793a\uff0c\u57282.5\u5c0f\u65f6\u300124\u5c0f\u65f6\u548c12\u5468\u7684\u65f6\u95f4\u70b9\uff0cExeatide\u201c\u5728\u7edf\u8ba1\u5b66\u4e0a\u663e\u8457\u201d\u964d\u4f4e\u4e86\u9885\u5185\u538b\uff0cInvex\u5c06\u5176\u63cf\u8ff0\u4e3a\u201c\u5feb\u901f\u548c\u6301\u7eed\u201d\u3002 \u5728\u6b21\u8981\u7ec8\u70b9\u5305\u62ec\u5934\u75db\u548c\u89c6\u529b\u65b9\u9762\uff0cExeatide\u4e5f\u663e\u793a\u51fa\u548c\u853c\u7684\u7ed3\u679c\u3002 \u6d4b\u91cf\u7684\u5934\u75db\u9891\u7387\u7a81\u51fa\u4e86\u7edf\u8ba1\u4e0a\u663e\u8457\u7684\uff0c\u6709\u76ca\u7684\u51cf\u5c11\u6bcf\u6708\u5934\u75db\u5929\u6570\u7684Exenatide\u6cbb\u7597\u7684\u60a3\u8005\u3002 \u5728\u89c6\u529b\u65b9\u9762\uff0c\u8bd5\u9a8c\u8bc1\u660e\uff0c\u670d\u7528Exenatide\u7684\u60a3\u8005\u201c\u5728\u7edf\u8ba1\u5b66\u4e0a\u6709\u663e\u8457\u6539\u5584\u201d\u3002 \u8be5\u516c\u53f8\u8868\u793a:\u201c\u6211\u4eec\u76f8\u4fe1\uff0c\u8fd9\u4e9b\u4e8c\u671f\u6570\u636e\u6709\u529b\u5730\u652f\u6301\u5c06Presendin (Invex\u7684\u4e13\u5229Exenatide\u914d\u65b9)\u57282021\u5e74\u4e0a\u534a\u5e74\u8f6c\u5165\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\u201d \u6839\u636eInvex\u8463\u4e8b\u957fJason Loveridge\u535a\u58eb\u7684\u8bf4\u6cd5\uff0c\u5728\u8bbe\u8ba1\u548c\u6267\u884cInvex\u7684\u5355\u671f3\u671f\u6ce8\u518c\u7814\u7a76\u65f6\uff0c\u8bd5\u9a8c\u7684\u6570\u636e\u662f\u201c\u65e0\u4ef7\u7684\u201d\uff0c\u5e76\u201c\u589e\u52a0\u4e86\u6211\u4eec\u7684\u4fe1\u5fc3\uff0c\u5373Presendin\u5c06\u88ab\u8bc1\u660e\u662f\u4e00\u4e2a\u6709\u4ef7\u503c\u7684\u6cbb\u7597\u65b9\u6848\uff0c\u5bf9\u60a3\u6709IIH\u7684\u60a3\u8005\uff0c\u76ee\u524d\u6ca1\u6709\u6279\u51c6\u6216\u6709\u6548\u7684\u836f\u7269\u3002\u201d \u878d\u8d44\u53d1\u5c55 \u51ed\u501f\u5f3a\u52b2\u7684\u4e1a\u7ee9\u548c\u5373\u5c06\u8fdb\u884c\u7684\u4e09\u671f\u8bd5\u9a8c\uff0cInvex\u8fc5\u901f\u5411\u673a\u6784\u6295\u8d44\u8005\u3001\u4e13\u4e1a\u4eba\u58eb\u3001\u7ecf\u9a8c\u4e30\u5bcc\u7684\u6fb3\u5927\u5229\u4e9a\u548c\u6d77\u5916\u6295\u8d44\u8005\u8fdb\u884c\u4e86\u914d\u552e\uff0c\u7b79\u96c6\u4e862,620\u4e07\u6fb3\u5143\u3002 Invex\u4ee5\u6bcf\u80a11.30\u6fb3\u5143\u7684\u53d1\u884c\u4ef7\u53d1\u884c\u4e862,015\u4e07\u80a1\u5df2\u7f34\u8db3\u80a1\u672c\u7684\u65b0\u666e\u901a\u80a1\uff0c\u8f83\u5e02\u573a\u5e73\u5747\u4ef7\u683c\u7ea6\u67094%\u7684\u6298\u8ba9\uff0c\u8f83\u516c\u53f85\u670818\u65e5\u505c\u724c\u524d\u7684\u6536\u76d8\u4ef7\u670913%\u7684\u6298\u8ba9\u3002 \u6b64\u6b21\u914d\u80a1\u8ba1\u5212\u5206\u4e24\u6279\u8fdb\u884c:\u7b2c\u4e00\u6279\u5c06\u4ee5\u6bcf\u80a11.30\u6fb3\u5143\u7684\u4ef7\u683c\u53d1\u884c1,250\u4e07\u80a1\uff0c\u7b79\u8d441,625\u4e07\u6fb3\u5143;\u7b2c\u4e8c\u6279\u5c06\u4ee5\u6bcf\u80a11.30\u6fb3\u5143\u7684\u4ef7\u683c\u518d\u53d1\u884c765\u4e07\u80a1\uff0c\u7b79\u8d44995\u4e07\u6fb3\u5143\u3002 \u7136\u800c\uff0cTranche 2\u7684\u5b8c\u6210\u53d6\u51b3\u4e8eInvex\u7684\u7279\u522b\u80a1\u4e1c\u5927\u4f1a(EGM)\u7684\u6279\u51c6\uff0c\u9884\u8ba12020\u5e746\u670829\u65e5\u6216\u524d\u540e\u4e3e\u884c\u3002 \u8be5\u516c\u53f8\u4ece\u73b0\u6709\u6295\u8d44\u8005\u90a3\u91cc\u83b7\u5f97\u4e86\u603b\u8ba11050\u4e07\u6fb3\u5143\u7684\u57fa\u77f3\u6295\u8d44\u627f\u8bfa\uff0c\u5176\u4e2d500\u4e07\u7f8e\u5143\u6765\u81eaTattarang\uff0c\u5373\u524dMinderoo Group\u3002 Loveridge\u535a\u58eb\u89e3\u91ca\u8bf4\uff0cInvex\u516c\u53f8\u5c06\u5229\u7528\u7b79\u96c6\u5230\u7684\u8d44\u91d1\u8fdb\u884c\u7b2c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5e76\u8d44\u52a9\u7b2c\u4e8c\u4e2a\u4e34\u5e8a\u9879\u76ee\uff0c\u5f88\u53ef\u80fd\u662fIIH-WOP\uff0c\u8fd9\u662f\u7b2c\u4e8c\u4e2a\u5b64\u513f\u9002\u5e94\u75c7\u3002 \u4ed6\u8bf4:\u201c\u8fd9\u7b14\u8d44\u91d1\u4e3a\u8be5\u516c\u53f8\u63d0\u4f9b\u4e86\u4e00\u4e2a\u6e05\u6670\u7684\u8f68\u8ff9\uff0c\u4f7f\u5176\u80fd\u591f\u5728\u5e02\u573a\u4e0a\u6ca1\u6709\u4efb\u4f55\u6279\u51c6\u6cbb\u7597\u7684\u91cd\u8981\u5b64\u513f\u75be\u75c5\u4e2d\u83b7\u5f97III\u671f\u4e34\u5e8a\u7ed3\u679c\u3002\u201d \u5728\u914d\u552e\u5b8c\u6210\u540e\uff0cInvex\u8868\u793a\uff0c\u73b0\u91d1\u6ce8\u5165\u5c06\u4f7f\u8be5\u516c\u53f8\u8d22\u52a1\u72b6\u51b5\u826f\u597d\uff0c\u7ea63,660\u4e07\u6fb3\u5143\u73b0\u91d1\u5c06\u6ee1\u8db3\u5176\u4e34\u5e8a\u548c\u5176\u4ed6\u76ee\u6807\u3002 Invex\u80a1\u4ef7\u5728\u65e9\u76d8\u4ea4\u6613\u4e2d\u4e0a\u6da8\u8d85\u8fc716%\uff0c\u8fbe\u52301.74\u6fb3\u5143\u3002<\/p>\n","protected":false},"author":5,"featured_media":7949,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Invex Therapeutics\u516c\u53f8\u7b79\u96c6\u4e862600\u4e07\u6fb3\u5143\uff0c\u8ba1\u5212\u8fdb\u884c\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c<\/title>\n<meta name=\"description\" content=\"\u4e24\u5929\u4ee5\u6765\u53d1\u5e03\u5176\u7b2c\u4e8c\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u548c\u201c\u660e\u786e\u8bc1\u636e\u201d\u5ba3\u5e03\u5176Exeatide\u836f\u7269\u662f\u6709\u6548\u964d\u4f4e\u9885\u5185\u538b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b(IIH)\u75c5\u4eba,Invex Therapeutics (ASX: IXC)\u8ddf\u8fdb\u4eca\u5929\u65e9\u4e0a\u5ba3\u5e03\u6210\u529f\u76842620\u4e07\u6fb3\u5143\u878d\u8d44\u7684\u5f62\u5f0f\u914d\u80a1\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics\u516c\u53f8\u7b79\u96c6\u4e862600\u4e07\u6fb3\u5143\uff0c\u8ba1\u5212\u8fdb\u884c\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\" \/>\n<meta property=\"og:description\" content=\"\u4e24\u5929\u4ee5\u6765\u53d1\u5e03\u5176\u7b2c\u4e8c\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u548c\u201c\u660e\u786e\u8bc1\u636e\u201d\u5ba3\u5e03\u5176Exeatide\u836f\u7269\u662f\u6709\u6548\u964d\u4f4e\u9885\u5185\u538b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b(IIH)\u75c5\u4eba,Invex Therapeutics (ASX: IXC)\u8ddf\u8fdb\u4eca\u5929\u65e9\u4e0a\u5ba3\u5e03\u6210\u529f\u76842620\u4e07\u6fb3\u5143\u878d\u8d44\u7684\u5f62\u5f0f\u914d\u80a1\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-raises-plans-phase-3-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-22T01:32:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T18:02:05+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/05\/Invex-Therapeutics-ASX-IXC-Idiopathic-Intracranial-Hypertension-headache.jpg\" \/>\n<meta name=\"author\" content=\"Small Caps\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Invex Therapeutics\u516c\u53f8\u7b79\u96c6\u4e862600\u4e07\u6fb3\u5143\uff0c\u8ba1\u5212\u8fdb\u884c\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\" \/>\n<meta name=\"twitter:description\" content=\"\u4e24\u5929\u4ee5\u6765\u53d1\u5e03\u5176\u7b2c\u4e8c\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u548c\u201c\u660e\u786e\u8bc1\u636e\u201d\u5ba3\u5e03\u5176Exeatide\u836f\u7269\u662f\u6709\u6548\u964d\u4f4e\u9885\u5185\u538b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b(IIH)\u75c5\u4eba,Invex Therapeutics (ASX: IXC)\u8ddf\u8fdb\u4eca\u5929\u65e9\u4e0a\u5ba3\u5e03\u6210\u529f\u76842620\u4e07\u6fb3\u5143\u878d\u8d44\u7684\u5f62\u5f0f\u914d\u80a1\u3002\" \/>\n<meta name=\"twitter:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/05\/Invex-Therapeutics-ASX-IXC-Idiopathic-Intracranial-Hypertension-headache.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Small Caps\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-raises-plans-phase-3-clinical-trial\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-raises-plans-phase-3-clinical-trial\/\",\"name\":\"Invex Therapeutics\u516c\u53f8\u7b79\u96c6\u4e862600\u4e07\u6fb3\u5143\uff0c\u8ba1\u5212\u8fdb\u884c\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2020-05-22T01:32:02+00:00\",\"dateModified\":\"2023-08-29T18:02:05+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\"},\"description\":\"\u4e24\u5929\u4ee5\u6765\u53d1\u5e03\u5176\u7b2c\u4e8c\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u548c\u201c\u660e\u786e\u8bc1\u636e\u201d\u5ba3\u5e03\u5176Exeatide\u836f\u7269\u662f\u6709\u6548\u964d\u4f4e\u9885\u5185\u538b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b(IIH)\u75c5\u4eba,Invex Therapeutics (ASX: IXC)\u8ddf\u8fdb\u4eca\u5929\u65e9\u4e0a\u5ba3\u5e03\u6210\u529f\u76842620\u4e07\u6fb3\u5143\u878d\u8d44\u7684\u5f62\u5f0f\u914d\u80a1\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-raises-plans-phase-3-clinical-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-raises-plans-phase-3-clinical-trial\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-raises-plans-phase-3-clinical-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics\u516c\u53f8\u7b79\u96c6\u4e862600\u4e07\u6fb3\u5143\uff0c\u8ba1\u5212\u8fdb\u884c\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\",\"name\":\"Small Caps\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"caption\":\"Small Caps\"},\"description\":\"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=5\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics\u516c\u53f8\u7b79\u96c6\u4e862600\u4e07\u6fb3\u5143\uff0c\u8ba1\u5212\u8fdb\u884c\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c","description":"\u4e24\u5929\u4ee5\u6765\u53d1\u5e03\u5176\u7b2c\u4e8c\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u548c\u201c\u660e\u786e\u8bc1\u636e\u201d\u5ba3\u5e03\u5176Exeatide\u836f\u7269\u662f\u6709\u6548\u964d\u4f4e\u9885\u5185\u538b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b(IIH)\u75c5\u4eba,Invex Therapeutics (ASX: IXC)\u8ddf\u8fdb\u4eca\u5929\u65e9\u4e0a\u5ba3\u5e03\u6210\u529f\u76842620\u4e07\u6fb3\u5143\u878d\u8d44\u7684\u5f62\u5f0f\u914d\u80a1\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics\u516c\u53f8\u7b79\u96c6\u4e862600\u4e07\u6fb3\u5143\uff0c\u8ba1\u5212\u8fdb\u884c\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c","og_description":"\u4e24\u5929\u4ee5\u6765\u53d1\u5e03\u5176\u7b2c\u4e8c\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u548c\u201c\u660e\u786e\u8bc1\u636e\u201d\u5ba3\u5e03\u5176Exeatide\u836f\u7269\u662f\u6709\u6548\u964d\u4f4e\u9885\u5185\u538b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b(IIH)\u75c5\u4eba,Invex Therapeutics (ASX: IXC)\u8ddf\u8fdb\u4eca\u5929\u65e9\u4e0a\u5ba3\u5e03\u6210\u529f\u76842620\u4e07\u6fb3\u5143\u878d\u8d44\u7684\u5f62\u5f0f\u914d\u80a1\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-raises-plans-phase-3-clinical-trial\/","og_site_name":"smallcapsCN","article_published_time":"2020-05-22T01:32:02+00:00","article_modified_time":"2023-08-29T18:02:05+00:00","og_image":[{"url":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/05\/Invex-Therapeutics-ASX-IXC-Idiopathic-Intracranial-Hypertension-headache.jpg"}],"author":"Small Caps","twitter_card":"summary_large_image","twitter_title":"Invex Therapeutics\u516c\u53f8\u7b79\u96c6\u4e862600\u4e07\u6fb3\u5143\uff0c\u8ba1\u5212\u8fdb\u884c\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c","twitter_description":"\u4e24\u5929\u4ee5\u6765\u53d1\u5e03\u5176\u7b2c\u4e8c\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u548c\u201c\u660e\u786e\u8bc1\u636e\u201d\u5ba3\u5e03\u5176Exeatide\u836f\u7269\u662f\u6709\u6548\u964d\u4f4e\u9885\u5185\u538b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b(IIH)\u75c5\u4eba,Invex Therapeutics (ASX: IXC)\u8ddf\u8fdb\u4eca\u5929\u65e9\u4e0a\u5ba3\u5e03\u6210\u529f\u76842620\u4e07\u6fb3\u5143\u878d\u8d44\u7684\u5f62\u5f0f\u914d\u80a1\u3002","twitter_image":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/05\/Invex-Therapeutics-ASX-IXC-Idiopathic-Intracranial-Hypertension-headache.jpg","twitter_misc":{"Written by":"Small Caps"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-raises-plans-phase-3-clinical-trial\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-raises-plans-phase-3-clinical-trial\/","name":"Invex Therapeutics\u516c\u53f8\u7b79\u96c6\u4e862600\u4e07\u6fb3\u5143\uff0c\u8ba1\u5212\u8fdb\u884c\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2020-05-22T01:32:02+00:00","dateModified":"2023-08-29T18:02:05+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74"},"description":"\u4e24\u5929\u4ee5\u6765\u53d1\u5e03\u5176\u7b2c\u4e8c\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u548c\u201c\u660e\u786e\u8bc1\u636e\u201d\u5ba3\u5e03\u5176Exeatide\u836f\u7269\u662f\u6709\u6548\u964d\u4f4e\u9885\u5185\u538b\u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b(IIH)\u75c5\u4eba,Invex Therapeutics (ASX: IXC)\u8ddf\u8fdb\u4eca\u5929\u65e9\u4e0a\u5ba3\u5e03\u6210\u529f\u76842620\u4e07\u6fb3\u5143\u878d\u8d44\u7684\u5f62\u5f0f\u914d\u80a1\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-raises-plans-phase-3-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-raises-plans-phase-3-clinical-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-raises-plans-phase-3-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics\u516c\u53f8\u7b79\u96c6\u4e862600\u4e07\u6fb3\u5143\uff0c\u8ba1\u5212\u8fdb\u884c\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74","name":"Small Caps","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","caption":"Small Caps"},"description":"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.","url":"https:\/\/smallcapscn.x5view.co\/?author=5"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1221"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1221"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1221\/revisions"}],"predecessor-version":[{"id":7948,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1221\/revisions\/7948"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/7949"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}